Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Open-label, Multi-center Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With an Androgen Receptor Pathway Inhibitor (ARPI) in Adult Participants With PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT07226986 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT07226986
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07226986 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Open-label, Multi-center Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With an Androgen Receptor Pathway Inhibitor (ARPI) in Adult Participants With PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC)
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 5, 2025
Completion date
September 13, 2029
Enrollment
123 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

psma-positive metastatic castration resistant prostate cancer (mcrpc) with prior exposure to one prior arpi who are candidates for taxane-based chemotherapy